Odd Twist in Phase 3 Alzheimer's Trial for Novel Tau Inhibitor
Although the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators insist there's more to the story ― especially with the control agent used.
Medscape Medical News
source https://www.medscape.com/viewarticle/984863?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/984863?src=rss
Comments
Post a Comment